HC Wainwright reissued their buy rating on shares of Acer Therapeutics (NASDAQ:ACER) in a research report released on Friday. The firm currently has a $50.00 price objective on the biopharmaceutical company’s stock.
Other equities research analysts have also issued reports about the stock. Roth Capital assumed coverage on shares of Acer Therapeutics in a report on Monday, February 26th. They issued a buy rating and a $70.00 target price on the stock. William Blair assumed coverage on shares of Acer Therapeutics in a report on Friday, February 16th. They issued an outperform rating on the stock. Finally, ValuEngine lowered shares of Acer Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $60.00.
Acer Therapeutics (NASDAQ:ACER) opened at $18.16 on Friday. Acer Therapeutics has a twelve month low of $5.70 and a twelve month high of $22.63. The firm has a market cap of $133.79, a P/E ratio of -9.36 and a beta of 2.53.
A number of institutional investors and hedge funds have recently bought and sold shares of ACER. Stonepine Capital Management LLC acquired a new stake in Acer Therapeutics in the fourth quarter worth $1,385,000. Perceptive Advisors LLC acquired a new stake in Acer Therapeutics in the fourth quarter worth $2,091,000. Ardsley Advisory Partners acquired a new stake in Acer Therapeutics in the fourth quarter worth $212,000. Finally, J. Goldman & Co LP acquired a new stake in Acer Therapeutics in the fourth quarter worth $1,496,000. Institutional investors own 7.54% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “HC Wainwright Reaffirms Buy Rating for Acer Therapeutics (ACER)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2018/03/13/hc-wainwright-reaffirms-buy-rating-for-acer-therapeutics-acer.html.
Acer Therapeutics Company Profile
Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.
Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.